Lupin announces USFDA approval of supplemental new drug for treating Trichomoniasis
Lupin Limited announced on Thursday that United States Food & Drug Administration (USFDA) has approved the company’s supplemental new drug application (sNDA) to expand the use of Solosec (Secnidazole) to include the treatment of Trichomoniasis in adults.
Trichomoniasis vaginalis is the most common non-viral, curable sexually transmitted infection (STI) in the US. The drug is equivalent to the reference listed drug product (RLD), Macrodantin capsules, 25 mg, 50 mg & 100 mg, of Alvogen Malta Operations Limited.
Solosec is the first and only single-dose oral prescription antimicrobial agent for the treatment of both trichomoniasis and bacterial vaginosis approved by FDA in the US.
Reacting to this, the company’s stock today increased by 1.80 per cent and made an intraday high of Rs 1,166.90 per share.
Lupin is a pharmaceutical company headquartered in Mumbai. The company develops and commercialises a wide range of branded & generic formulations, biotechnology products as well as APIs in over 100 markets across the globe.
According to BSE data, the stock traded at a P/E multiple of 41.32 and a price-to-book ratio of 2.80. The stock has a 52-week high and a 52-week low of Rs 1,267.50 and Rs 828.65, respectively.
At 11.39 am, the stock of the company was trading at Rs 1,154.15, up by 0.69 per cent on BSE.